Sucampo Announces Presentation of Results on Lubiprostone in Pediatric Functional Constipation at NASPGHAN 2013
October 10, 2013 20:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of results from a Phase 3, open-label safety and efficacy...
Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation
October 08, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced clinical data showing that lubiprostone is efficacious and well tolerated in...
Sucampo to Present Data on AMITIZA(R) (Lubiprostone) in Opioid-Induced Constipation at 24th Annual AAPM Meeting
September 27, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the poster presentation of data evaluating the long-term safety of...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at BioCentury(R) NewsMakers in the Biotech Industry 2013 Conference
September 20, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
September 12, 2013 19:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will present four...
Sucampo to Present Results From Four Phase 3 Studies of AMITIZA(R) (lubiprostone) for Opioid-Induced Constipation at PAINWeek 2013
September 04, 2013 20:05 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") will be presenting data from four separate phase 3 studies evaluating the overall efficacy of...
Sucampo Begins Search for New CEO
August 08, 2013 16:01 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced that it has begun the search for a new Chief Executive Officer (CEO). Sucampo...
Sucampo Pharmaceuticals, Inc. Reports Second Quarter and Six Months 2013 Financial and Operating Results
August 08, 2013 16:01 ET
|
Sucampo Pharmaceuticals Inc
Company Reports Profitable Quarter and Will Provide Earnings Guidance
Company to Host Conference Call Today at 5:00 pm Eastern
BETHESDA, Md., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Sucampo...
Sucampo Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608
August 07, 2013 20:02 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (Sucampo) today announced the positive top-line results of two recently completed clinical trials, a Phase...
Sucampo Pharmaceuticals Announces Second Quarter and Six Months 2013 Results and Operating Highlights Teleconference and Webcast
July 25, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., July 25, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and...